Stock Price, News, Quote and Profile of TEMPEST THERAPEUTICS INC(NASDAQ:TPST) stock

TEMPEST THERAPEUTICS INC

NASDAQ:TPST (1/3/2025, 8:06:35 PM)

After market: 0.9595 +0.01 (+0.8%)

0.9519

+0.09 (+10.89%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%14.58%

Sales Q2Q%N/A

CRS2.72

6 Month-52.88%

Overview

Earnings (Last)11-12 2024-11-12/amc

Earnings (Next)N/A N/A

Ins Owners0.24%

Inst Owners22.43%

Market Cap41.54M

Shares43.64M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts86.67

Short Float %7.4%

Short Ratio1.39

IPO10-04 2012-10-04

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company is headquartered in Brisbane California, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Company Info

TEMPEST THERAPEUTICS INC

2000 Sierra Point Parkway, Suite 400

Brisbane California CALIFORNIA

P: 14157988589

CEO: Louis Arcudi

Employees: 17

Website: https://www.tempesttx.com/

TPST News

a month ago - Tempest TherapeuticsTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...

a month ago - Tempest TherapeuticsTempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...

2 months ago - Tempest TherapeuticsTempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination...

TEMPEST THERAPEUTICS INC (TPST)

Nasdaq Stock Screener

USA Stock Screener